Table 3. Study participant treatments.
| African American N = 22 | Caucasian N = 49 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TAC | TC | TCH | AA Total | TAC | TC | TCH | C. Total | Study Total | |
| Treatment 1 | 10 (45%) | 6 (27%) | 6 (27%) | 22 (%) | 29 (59%) | 15 (31%) | 5 (10%) | 49 (%) | 71 (100%) |
| Surgery 1 | |||||||||
| Biopsy | 3 (14%) | 0 | 0 | 3 (14%) | 2 (4%) | 0 | 0 | 2 (4%) | 5 (7%) |
| Lumpectomy | 4 (18%) | 0 | 1 (5%) | 5 (23%) | 8 (16%) | 6 (12%) | 1 (2%) | 15 (31%) | 20 (28%) |
| Segmental | 1 (5%) | 5 (23%) | 3 (14%) | 9 (41%) | 1 (2%) | 5 (10%) | 0 | 6 (13%) | 15 (23%) |
| Simple | 2 (9%) | 1 (5%) | 2 (9%) | 5 (23%) | 18 (37%) | 3 (6%) | 4 (8%) | 25 (52%) | 30 (42%) |
| Neoadjuvant 1 | |||||||||
| Yes | 3 (14%) | 0 | 1 (5%) | 4 (18%) | 2 (4%) | 1 (2%) | 0 | 3 (6%) | 7 (10%) |
| No | 7 (32%) | 6 (27%) | 5 (23%) | 18 (82%) | 27 (55%) | 14 (29%) | 5 (10%) | 46 (94%) | 64 (90%) |
| Radiotherapy 1 | |||||||||
| Yes | 9 (41%) | 5 (23%) | 5 (23%) | 19 (86%) | 23 (47%) | 12 (24%) | 1 (2%) | 36 (73%) | 55 (77%) |
| No | 1 (5%) | 1 (5%) | 1 (5%) | 3 (14%) | 6 (12%) | 3 (6%) | 4 (8%) | 13 (27%) | 16 (23%) |
1Frequency (percentage of study participants for the category)